MAZE

Maze Therapeutics

• TipRanks·4d ago

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• Reuters·04/02 20:12

  Maze Therapeutics President R&D, CMO Harold Bernstein disposes shares worth $0.4 million

• Reuters·04/02 20:11

  Maze SVP Finance Amy Bachrodt disposes Maze Therapeutics shares worth $0.1 million

• Reuters·04/01 20:13

  Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $0.2 million

• Reuters·03/31 20:21

  Maze Therapeutics director Neil Kumar files initial beneficial ownership statement

• Dow Jones·03/31 16:22

  Maze Therapeutics Price Target Raised to $58.00/Share From $52.00 by JP Morgan

• Dow Jones·03/31 16:22

  Maze Therapeutics Is Maintained at Overweight by JP Morgan

• Benzinga·03/31 16:12

  JP Morgan Maintains Overweight on Maze Therapeutics, Raises Price Target to $58

• TipRanks·03/31 10:59

  J.P. Morgan Sticks to Its Buy Rating for Maze Therapeutics, Inc. (MAZE)

• TipRanks·03/31 10:51

  Maze Therapeutics price target raised to $58 from $52 at JPMorgan

• Reuters·03/31 07:39

  U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks

• Reuters·03/31 04:21

  MAZE THERAPEUTICS INC <MAZE.O>: JP MORGAN RAISES TARGET PRICE TO $58 FROM $52

• TipRanks·03/31 02:15

  Maze Therapeutics, Inc. (MAZE) Gets a Buy from Mizuho Securities

• TipRanks·03/28 14:37

  Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital

• Seeking Alpha·03/27 19:09

  Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop